Na
Non verificato

Natera, Inc.

Di cosa scriviamo

BiotecnologiaIndustriaMedicina - VarieOncologiaSalute
22/07/2026
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Scienza
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
1.00
16/07/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
1.00
09/07/2026
Sanità
Scienza
Farmaceutica
Oncologia
Tecnica
Biotecnologia
Medicina - Varie
Salute
Industria
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
1.00
06/07/2026
Oncologia
Attrezzature medico-sanitarie
Salute
Biotecnologia
Medicina - Varie
Eventi
Fiere
Industria
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
1.00
29/06/2026
Mercato del lavoro
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
1.00
25/06/2026
Multimedialità
Mercato del lavoro
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
1.00
24/06/2026
Industria
Oncologia
Salute
Vetrine/Shopping
Biotecnologia
Sanità
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
1.00
23/06/2026
Industria
Oncologia
Salute
Vetrine/Shopping
Biotecnologia
Sanità
NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
1.00
18/06/2026
Fiere
Eventi
Industria
Oncologia
Salute
Biotecnologia
Scienza
Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress
1.00
04/06/2026
Mercato del lavoro
Industria
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Farmaceutica
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0